May 28, 2020 8:30 am EDT Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
May 14, 2020 4:15 pm EDT Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
Feb 10, 2020 8:30 am EST Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
Dec 18, 2019 3:00 pm EST Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Jul 24, 2019 9:25 am EDT Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
